Study title:
Van Santen HM. Improved Radiation Protection of the Thyroid Gland with Thyroxine, Methimazole, and Potassium Iodide during Diagnostic and Therapeutic Use of Radiolabeled Metaiodobenzylguanidine in Children with Neuroblastoma, Cancer 2003; 98: 389-396 Van Santen HM. Improved Radiation Protection of the Thyroid Gland with Thyroxine, Methimazole, and Potassium Iodide during Diagnostic and Therapeutic Use of Radiolabeled Metaiodobenzylguanidine in Children with Neuroblastoma, Cancer 2003; 98: 389-396
Type of medicine: Medicines containing chemical active substances
|
Therapeutic area: Endocrine System Diseases
|
Brands: Please see report, Please see report, Please see report, Please see report |
MAH holders: Please see report, Please see report, Please see report, Please see report |
Assessment: |
Active substance: OBIDOXIME |
ATC code: V81C
|
Document link:
|
Document date:
|
Study number: |
EudraCT number:
|
Scope of study: |
Population of study subjects:
|
Preterm newborn Infants
|
Newborn infants
(1 to 27 days)
|
Infants and toddlers
(28 days to 24 months)
|
Children
(2 to 11 years)
|
Adolescents
(12 to 18 years)
|
|
-
|
-
|
-
|
-
|
-
|